GENPF (Genix Pharmaceuticals) ROC %: -7.25% (As of Jan. 2026)


What is Genix Pharmaceuticals ROC %?

Genix Pharmaceuticals GENPF ROC % is -7.25% as of Jan. 2026. The stock has 3 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Genix Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Jan. 2026 was -7.25%.

As of today (2026-07-01), Genix Pharmaceuticals's WACC % is 14.03%. Genix Pharmaceuticals's ROC % is -9.91% (calculated using TTM income statement data). Genix Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Genix Pharmaceuticals  (OTCPK:GENPF) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Genix Pharmaceuticals's WACC % is 14.03%. Genix Pharmaceuticals's ROC % is -9.91% (calculated using TTM income statement data). Genix Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Genix Pharmaceuticals ROC % Related Terms


Genix Pharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Genix Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genix Pharmaceuticals ROC % Chart

Genix Pharmaceuticals Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -33.65 -19.36 -29.69 -22.21 -12.86

Genix Pharmaceuticals Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.17 -9.53 -12.91 -10.38 -7.25

Genix Pharmaceuticals ROC % Calculation

Genix Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Oct. 2025 is calculated as:

ROC % (A: Oct. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Oct. 2024 ) + Invested Capital (A: Oct. 2025 ))/ count )
=-0.109 * ( 1 - 0% )/( (0.774 + 0.921)/ 2 )
=-0.109/0.8475
=-12.86 %

where

Genix Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Jan. 2026 is calculated as:

ROC % (Q: Jan. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2025 ) + Invested Capital (Q: Jan. 2026 ))/ count )
=-0.068 * ( 1 - 0% )/( (0.921 + 0.956)/ 2 )
=-0.068/0.9385
=-7.25 %

where

Note: The Operating Income data used here is four times the quarterly (Jan. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -7.25% mean?
Genix Pharmaceuticals (GENPF) has a ROC % of -7.25% as of Jan. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Genix Pharmaceuticals and its competitors.
Is Genix Pharmaceuticals' ROC % too high?
Genix Pharmaceuticals' current ROC % is -7.25%.
How does Genix Pharmaceuticals' ROC % compare to ZTS and UTHR?
Genix Pharmaceuticals' ROC % of -7.25% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.46, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Genix Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genix Pharmaceuticals's current ROC % is -7.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genix Pharmaceuticals stock overvalued right now?
Genix Pharmaceuticals (GENPF) has a current ROC % of -7.25%. The current ROC % is -7.25%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Genix Pharmaceuticals (GENPF), the current ROC % is -7.25% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genix Pharmaceuticals Business Description

Other Exchanges GENX:Canada
Address 1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company focused on the research, development, manufacturing, sales, and distribution of novel, branded generic ophthalmic drugs, and ophthalmic OTC products. It operates as a formulator, manufacturer, licensor, and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its ophthalmic products portfolio comprises different kinds of eye ointments (pending approval), and eye drops. Geographically the company operates only in Canada.